Antonio Solinas

TL;DR: In this cohort of patients, life expectancy is relatively long, in agreement with the morbidity data showing a slowly progressive disease.

TL;DR: High proportion of patients with HBsAg‐positive compensated cirrhosis do not experience worsening of their condition for several years, but once decompensation occurs life expectancy is poor, and European, white patients with compensated Cirrhosis type B are at consistent risk for HCC.

TL;DR: This analysis did not detect any significant benefit of interferon alfa on morbidity in patients with compensated cirrhosis type C, although it suggests a reduction in complications of Cirrhosis for those with a sustained response to therapy, and it indicates the need for better therapies.

TL;DR: The incidence of HBsAg loss is about 0.8% in cirrhosis type B and prognostic factors for clearance are initial HBeAg positivity and therapy with alpha interferon.

TL;DR: Eighty patients with chronic hepatitis C who completed a previously reported randomized controlled trial on the efficacy of interferon‐α2b were followed up for at least 36 mo after therapy discontinuation, finding sex, age, hepatitis C virus antibody status, source of infection and pretreatment levels of ALT were not predictive of long‐term response.